Camrelizumab in Combination With Neoadjuvant Chemotherapy

Phase 2UNKNOWN

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Soft Tissue Sarcoma

Conditions

Soft Tissue Sarcoma

Trial Timeline

Oct 19, 2020 → Mar 19, 2024

NCT ID

NCT04606108

About Camrelizumab in Combination With Neoadjuvant Chemotherapy

Camrelizumab in Combination With Neoadjuvant Chemotherapy is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Soft Tissue Sarcoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT04606108. Target conditions include Soft Tissue Sarcoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04606108	Phase 2	UNKNOWN	Oct 19, 2020	Mar 19, 2024	Soft Tissue Sarcoma
NCT04294511	Phase 2	UNKNOWN	Dec 26, 2019	Sep 16, 2023	Osteosarcoma

Competing Products

20 competing products in Soft Tissue Sarcoma

See all competitors

Product	Company	Stage	Hype Score
Olaratumab + Doxorubicin + Ifosfamide + Mesna	Eli Lilly	Phase 1	33
Anlotinib Hydrochloride	Sun Pharmaceutical	Phase 2	52
Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV	Eisai	Phase 3	77
Eribulin mesylate	Eisai	Pre-clinical	23
E7389	Eisai	Phase 2	52
eribulin mesylate	Eisai	Phase 2	52
Olaratumab + Gemcitabine + Docetaxel + Placebo	Eli Lilly	Phase 1/2	41
LY573636-sodium	Eli Lilly	Phase 2	52
Olaratumab	Eli Lilly	Pre-clinical	23
Olaratumab + Doxorubicin + Placebo	Eli Lilly	Phase 3	77
Olaratumab + Doxorubicin	Eli Lilly	Phase 1	33
Olaratumab + Doxorubicin	Eli Lilly	Phase 1	33
Olaratumab + Pembrolizumab (KEYTRUDA®)	Eli Lilly	Phase 1	33
Olaratumab + doxorubicin	Eli Lilly	Phase 1/2	41
Trabectedin	Johnson & Johnson	Pre-clinical	23
Doxorubicin + Trabectedin + Dexamethasone	Johnson & Johnson	Phase 1	33
Apatinib Mesylate, doxorubicin, ifosfamide	Jiangsu Hengrui Medicine	Phase 2	52
Durvalumab and Tremelimumab + Doxorubicin	AstraZeneca	Phase 2	52
Standard arm: Trabectedin in monotherapy + Experimental arm: Trabectedin + Olaparib	AstraZeneca	Phase 2	52
trabectedin + olaparib	AstraZeneca	Phase 1	33

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved

Remimazolam TosilateApproved

Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved

ImrecoxibApproved

IvarmacitinibApproved